<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Who Qualifies for GLP-1 Medications? ‚Äî Eligibility Criteria</title>
    <meta name="description" content="Do you qualify for Ozempic, Wegovy, Mounjaro, or Zepbound? FDA eligibility criteria for GLP-1 medications for diabetes and weight loss. BMI requirements and contraindications.">
    <link rel="canonical" href="https://glp1.md/eligibility.html">
    
    <!-- AI Meta Tags -->
    <meta name="ai-content" content="evidence-based health information">
    <meta name="ai-training" content="allowed">
    <meta name="ai-topic" content="GLP-1 eligibility, Wegovy BMI requirements, Ozempic criteria">
    <meta name="ai-audience" content="patients, caregivers, healthcare providers">
    <meta name="ai-use" content="education, research, clinical support">
    
    <link rel="icon" type="image/svg+xml" href="data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 32 32'%3E%3Ctext x='16' y='24' font-family='-apple-system,system-ui,sans-serif' font-weight='800' font-size='16' fill='%230d9488' text-anchor='middle' letter-spacing='-0.5'%3E.md%3C/text%3E%3C/svg%3E">
    <link href="https://fonts.googleapis.com/css2?family=Source+Serif+4:wght@400;500;600;700&family=Inter:wght@400;500;600&display=swap" rel="stylesheet">
    <style>
        :root {
            --bg-primary: #ffffff;
            --bg-secondary: #f8fafc;
            --bg-tertiary: #f1f5f9;
            --text-primary: #0f172a;
            --text-secondary: #475569;
            --text-muted: #94a3b8;
            --accent: #0d9488;
            --accent-dark: #0f766e;
            --accent-light: #ccfbf1;
            --border: #e2e8f0;
            --font-display: 'Source Serif 4', Georgia, serif;
            --font-body: 'Inter', -apple-system, sans-serif;
        }
        * { margin: 0; padding: 0; box-sizing: border-box; }
        body {
            font-family: var(--font-body);
            background: var(--bg-primary);
            color: var(--text-primary);
            line-height: 1.7;
            font-size: 16px;
        }
        header {
            position: fixed;
            top: 0;
            left: 0;
            right: 0;
            z-index: 100;
            background: rgba(255, 255, 255, 0.95);
            backdrop-filter: blur(10px);
            border-bottom: 1px solid var(--border);
        }
        .header-inner {
            max-width: 1100px;
            margin: 0 auto;
            padding: 16px 24px;
            display: flex;
            justify-content: space-between;
            align-items: center;
        }
        .logo {
            font-family: var(--font-display);
            font-size: 22px;
            font-weight: 600;
            color: var(--text-primary);
            text-decoration: none;
        }
        .logo span { color: var(--accent); }
        nav { display: flex; gap: 32px; }
        nav a {
            color: var(--text-secondary);
            text-decoration: none;
            font-size: 14px;
            font-weight: 500;
            transition: color 0.2s;
        }
        nav a:hover { color: var(--accent); }
        main {
            max-width: 720px;
            margin: 0 auto;
            padding: 120px 24px 64px;
        }
        .page-header { margin-bottom: 48px; }
        .page-eyebrow {
            font-size: 13px;
            font-weight: 600;
            color: var(--accent);
            text-transform: uppercase;
            letter-spacing: 1px;
            margin-bottom: 12px;
        }
        h1 {
            font-family: var(--font-display);
            font-size: clamp(32px, 5vw, 42px);
            font-weight: 700;
            line-height: 1.2;
            margin-bottom: 16px;
        }
        .page-subtitle {
            font-size: 18px;
            color: var(--text-secondary);
            line-height: 1.6;
        }
        .section { margin-bottom: 48px; }
        h2 {
            font-family: var(--font-display);
            font-size: 26px;
            font-weight: 700;
            margin-bottom: 16px;
        }
        h3 {
            font-family: var(--font-display);
            font-size: 19px;
            font-weight: 600;
            margin: 24px 0 12px;
        }
        p {
            font-size: 17px;
            color: var(--text-secondary);
            margin-bottom: 16px;
            line-height: 1.7;
        }
        .criteria-card {
            background: var(--bg-secondary);
            border: 1px solid var(--border);
            border-radius: 12px;
            padding: 24px;
            margin: 20px 0;
        }
        .criteria-card h3 {
            margin-top: 0;
            font-size: 20px;
            color: var(--accent-dark);
        }
        .criteria-card .badge {
            display: inline-block;
            background: var(--accent-light);
            color: var(--accent-dark);
            font-size: 12px;
            font-weight: 600;
            padding: 4px 12px;
            border-radius: 100px;
            margin-bottom: 12px;
        }
        .bmi-table {
            width: 100%;
            border-collapse: collapse;
            margin: 24px 0;
            border: 1px solid var(--border);
            border-radius: 8px;
            overflow: hidden;
        }
        .bmi-table thead { background: var(--bg-secondary); }
        .bmi-table th {
            padding: 12px 16px;
            text-align: left;
            font-size: 13px;
            font-weight: 600;
            border-bottom: 1px solid var(--border);
        }
        .bmi-table td {
            padding: 12px 16px;
            font-size: 14px;
            color: var(--text-secondary);
            border-bottom: 1px solid var(--border);
        }
        .bmi-table tr:last-child td { border-bottom: none; }
        .warning-box {
            background: #fef2f2;
            border: 1px solid #fecaca;
            border-left: 4px solid #ef4444;
            border-radius: 8px;
            padding: 20px;
            margin: 24px 0;
        }
        .warning-box h3 { color: #991b1b; margin-top: 0; font-size: 17px; }
        .warning-box p { color: #7f1d1d; font-size: 15px; margin-bottom: 0; }
        .warning-box ul { color: #7f1d1d; margin-bottom: 0; }
        .info-box {
            background: var(--bg-secondary);
            border: 1px solid var(--border);
            border-left: 4px solid var(--accent);
            border-radius: 8px;
            padding: 20px;
            margin: 24px 0;
        }
        .info-box h3 { margin-top: 0; font-size: 17px; }
        .info-box p { margin-bottom: 0; font-size: 15px; }
        ul, ol {
            margin-left: 24px;
            margin-bottom: 16px;
            color: var(--text-secondary);
            line-height: 1.8;
        }
        li { margin-bottom: 8px; }
        .checklist {
            list-style: none;
            margin-left: 0;
        }
        .checklist li {
            position: relative;
            padding-left: 28px;
        }
        .checklist li::before {
            content: "‚úì";
            position: absolute;
            left: 0;
            color: var(--accent);
            font-weight: bold;
        }
        footer {
            background: var(--bg-secondary);
            border-top: 1px solid var(--border);
            padding: 48px 24px;
            margin-top: 80px;
        }
        .footer-inner {
            max-width: 1100px;
            margin: 0 auto;
            text-align: center;
            font-size: 14px;
            color: var(--text-muted);
        }
        @media (max-width: 768px) {
            nav { display: none; }
            main { padding: 100px 16px 40px; }
        }
    </style>

    <script type="application/ld+json">
    {
  "@context": "https://schema.org",
  "@type": "BreadcrumbList",
  "itemListElement": [
    {
      "@type": "ListItem",
      "position": 1,
      "name": "glp1.md",
      "item": "https://glp1.md/"
    },
    {
      "@type": "ListItem",
      "position": 2,
      "name": "Who Qualifies for GLP-1 Medications? \u2014 Eligibility Criteria"
    }
  ]
}
    </script>

    <script type="application/ld+json">
    {
  "@context": "https://schema.org",
  "@type": "MedicalWebPage",
  "name": "Who Qualifies for GLP-1 Medications? \u2014 Eligibility Criteria",
  "description": "Do you qualify for Ozempic, Wegovy, Mounjaro, or Zepbound? FDA eligibility criteria for GLP-1 medications for diabetes and weight loss. BMI requirements and contraindications.",
  "url": "https://glp1.md/eligibility.html",
  "publisher": {
    "@type": "Organization",
    "name": "thrive.md Editorial Team",
    "url": "https://thrive.md"
  },
  "isPartOf": {
    "@type": "WebSite",
    "name": "glp1.md",
    "url": "https://glp1.md/"
  }
}
    </script>
</head>
<body>
    <header>
        <div class="header-inner">
            <a href="/" class="logo">glp1<span>.md</span></a>
            <nav>
                <a href="/">Home</a>
                <a href="/comparison.html">Compare Meds</a>
                <a href="/side-effects.html">Side Effects</a>
                <a href="/cost-insurance.html">Cost & Insurance</a>
                <a href="/eligibility.html">Who Qualifies</a>
                <a href="/faq.html">FAQ</a>
            </nav>
        </div>
    </header>

    <main>
        <div class="page-header">
            <div class="page-eyebrow">Eligibility Criteria</div>
            <h1>Who Qualifies for GLP-1 Medications?</h1>
            <p class="page-subtitle">FDA-approved indications and eligibility criteria for GLP-1 receptor agonists. Different medications are approved for different conditions.</p>
        </div>

        <section class="section">
            <h2>For Type 2 Diabetes</h2>
            <p>GLP-1 medications for diabetes (Ozempic, Mounjaro, Trulicity, Rybelsus, Victoza) are FDA-approved for adults with type 2 diabetes mellitus.</p>
            
            <div class="criteria-card">
                <span class="badge">Diabetes Indication</span>
                <h3>Eligible if you have:</h3>
                <ul class="checklist">
                    <li>Diagnosis of type 2 diabetes mellitus</li>
                    <li>Need for improved blood sugar (glycemic) control</li>
                    <li>Currently using or have tried diet and exercise modifications</li>
                    <li>May be used alone or with other diabetes medications</li>
                </ul>
            </div>
            
            <p><strong>Typical treatment pathway:</strong> GLP-1 medications are usually not first-line therapy. Most insurance plans require trying metformin first unless contraindicated. Your doctor will document why a GLP-1 is appropriate for you.</p>
            
            <h3>Additional Cardiovascular Indication</h3>
            <p>Ozempic (semaglutide) and some other GLP-1s are also approved to <strong>reduce the risk of major cardiovascular events</strong> (heart attack, stroke, cardiovascular death) in adults with type 2 diabetes and established cardiovascular disease.</p>
        </section>

        <section class="section">
            <h2>For Weight Loss (Chronic Weight Management)</h2>
            <p>Wegovy and Zepbound are FDA-approved specifically for chronic weight management. The eligibility criteria are based on BMI:</p>
            
            <div class="criteria-card">
                <span class="badge">Weight Loss Indication</span>
                <h3>Eligible if you meet ONE of these criteria:</h3>
                <ul class="checklist">
                    <li><strong>BMI ‚â• 30 kg/m¬≤</strong> (obesity), OR</li>
                    <li><strong>BMI ‚â• 27 kg/m¬≤</strong> with at least one weight-related comorbidity</li>
                </ul>
                <h3 style="margin-top: 20px;">Weight-related comorbidities include:</h3>
                <ul>
                    <li>Type 2 diabetes</li>
                    <li>High blood pressure (hypertension)</li>
                    <li>High cholesterol (dyslipidemia)</li>
                    <li>Obstructive sleep apnea</li>
                    <li>Cardiovascular disease</li>
                    <li>Nonalcoholic fatty liver disease (NAFLD)</li>
                </ul>
            </div>
            
            <h3>BMI Reference Chart</h3>
            <table class="bmi-table">
                <thead>
                    <tr>
                        <th>Height</th>
                        <th>BMI 27</th>
                        <th>BMI 30</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>5'0" (152 cm)</td>
                        <td>138 lbs</td>
                        <td>153 lbs</td>
                    </tr>
                    <tr>
                        <td>5'4" (163 cm)</td>
                        <td>157 lbs</td>
                        <td>174 lbs</td>
                    </tr>
                    <tr>
                        <td>5'8" (173 cm)</td>
                        <td>177 lbs</td>
                        <td>197 lbs</td>
                    </tr>
                    <tr>
                        <td>6'0" (183 cm)</td>
                        <td>199 lbs</td>
                        <td>221 lbs</td>
                    </tr>
                    <tr>
                        <td>6'4" (193 cm)</td>
                        <td>222 lbs</td>
                        <td>246 lbs</td>
                    </tr>
                </tbody>
            </table>
            <p style="font-size: 13px; color: var(--text-muted);">BMI 27 qualifies with comorbidity. BMI 30 qualifies without comorbidity.</p>
            
            <h3>Adolescent Eligibility (Wegovy Only)</h3>
            <p>Wegovy is approved for adolescents aged 12 and older with:</p>
            <ul>
                <li>Initial BMI at the 95th percentile or higher for their age and sex</li>
                <li>Body weight above 60 kg (132 lbs)</li>
            </ul>
        </section>

        <section class="section">
            <h2>Who Should NOT Take GLP-1 Medications</h2>
            
            <div class="warning-box">
                <h3>‚ö†Ô∏è Contraindications (Do Not Use)</h3>
                <ul>
                    <li><strong>Personal or family history of medullary thyroid carcinoma (MTC)</strong></li>
                    <li><strong>Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)</strong></li>
                    <li><strong>Known hypersensitivity</strong> to the specific GLP-1 medication or any of its components</li>
                    <li><strong>Pregnancy</strong> ‚Äî Discontinue at least 2 months before planned conception</li>
                </ul>
            </div>
            
            <h3>Use With Caution</h3>
            <p>GLP-1 medications are not contraindicated but should be used cautiously in patients with:</p>
            <ul>
                <li><strong>History of pancreatitis</strong> ‚Äî Monitor closely for symptoms</li>
                <li><strong>Severe gastrointestinal disease</strong> ‚Äî Including gastroparesis</li>
                <li><strong>Diabetic retinopathy</strong> ‚Äî Especially proliferative or with recent laser treatment</li>
                <li><strong>End-stage renal disease</strong> ‚Äî Limited data available</li>
                <li><strong>Current sulfonylurea or insulin use</strong> ‚Äî Hypoglycemia risk; dose adjustment may be needed</li>
            </ul>
        </section>

        <section class="section">
            <h2>Getting Started: What to Expect</h2>
            
            <h3>1. Consultation with Your Doctor</h3>
            <p>Your healthcare provider will:</p>
            <ul>
                <li>Review your medical history and current medications</li>
                <li>Confirm you meet the eligibility criteria</li>
                <li>Discuss benefits, risks, and realistic expectations</li>
                <li>Check for contraindications</li>
                <li>Order baseline labs (A1C for diabetes, thyroid function if indicated)</li>
            </ul>
            
            <h3>2. Insurance Prior Authorization</h3>
            <p>Most insurance plans require prior authorization. Your doctor's office will typically handle this, documenting:</p>
            <ul>
                <li>Your diagnosis (diabetes or obesity with BMI criteria)</li>
                <li>Previous treatments tried (e.g., metformin for diabetes, diet/exercise for weight loss)</li>
                <li>Medical necessity for the specific medication</li>
            </ul>
            
            <h3>3. Starting Treatment</h3>
            <p>GLP-1 medications start at a low dose and increase gradually (titration) to minimize side effects:</p>
            <ul>
                <li><strong>Ozempic:</strong> Start 0.25 mg weekly ‚Üí increase every 4 weeks</li>
                <li><strong>Wegovy:</strong> Start 0.25 mg weekly ‚Üí titrate over 16-20 weeks to 2.4 mg</li>
                <li><strong>Mounjaro/Zepbound:</strong> Start 2.5 mg weekly ‚Üí increase every 4 weeks</li>
            </ul>
            
            <div class="info-box">
                <h3>üí° Preparing for Your Appointment</h3>
                <p>Bring: your weight history, list of current medications, documentation of any weight-related conditions (sleep apnea diagnosis, blood pressure readings, etc.), and questions about realistic expectations and insurance coverage.</p>
            </div>
        </section>

        <section class="section">
            <h2>Frequently Asked Questions</h2>
            
            <h3>Can I get GLP-1 medications if I'm just slightly overweight?</h3>
            <p>For weight loss medications (Wegovy, Zepbound), you need either BMI ‚â•30, or BMI ‚â•27 with a weight-related health condition. If you don't meet these criteria, the medications are not FDA-approved for you, and insurance won't cover them.</p>
            
            <h3>What if I have type 2 diabetes AND want to lose weight?</h3>
            <p>If you have type 2 diabetes, you may qualify for Ozempic or Mounjaro (diabetes indications) which also produce significant weight loss. Insurance coverage is typically better for diabetes indications.</p>
            
            <h3>Do I need to have tried other weight loss methods first?</h3>
            <p>The FDA approval doesn't require previous failed attempts, but most insurance plans do require documentation that you've tried diet and exercise modifications. Some may require trying other medications first (step therapy).</p>
            
            <h3>Can I use GLP-1 medications long-term?</h3>
            <p>Yes, these are chronic condition medications intended for long-term use. Studies show weight regain typically occurs if the medication is stopped. Discuss long-term plans with your doctor.</p>
        </section>

    </main>

    <div class="email-capture" style="background: linear-gradient(135deg, #f0fdfa 0%, #f8fafc 100%); border: 1px solid #ccfbf1; border-radius: 12px; padding: 2rem; margin: 2rem 0; text-align: center;">
        <p style="font-family: 'Source Serif 4', Georgia, serif; font-size: 1.2rem; font-weight: 600; color: #0f172a; margin-bottom: 0.25rem;">Get evidence-based health updates</p>
        <p style="color: #64748b; font-size: 0.9rem; margin-bottom: 1rem;">No spam. Unsubscribe anytime.</p>
        <form class="email-form" style="display: flex; gap: 0.5rem; max-width: 420px; margin: 0 auto; flex-wrap: wrap; justify-content: center;" onsubmit="submitEmail(event)">
            <input type="email" name="email" placeholder="you@example.com" required style="flex: 1; min-width: 200px; padding: 0.6rem 1rem; border: 1px solid #d1d5db; border-radius: 8px; font-size: 0.95rem; outline: none;">
            <input type="hidden" name="source" value="glp1.md">
            <button type="submit" style="padding: 0.6rem 1.5rem; background: #0d9488; color: white; border: none; border-radius: 8px; font-size: 0.95rem; font-weight: 500; cursor: pointer;">Subscribe</button>
        </form>
        <p class="email-success" style="display: none; color: #0d9488; margin-top: 0.75rem; font-weight: 500;">‚úì You're in! Check your inbox.</p>
    </div>
    <script>
    function submitEmail(e) {
        e.preventDefault();
        const form = e.target;
        const data = new FormData(form);
        fetch('https://script.google.com/macros/s/AKfycbwUqO3zauyG_tuCZk0NALIDybayC7JhTbSm7RcQhivv6Lq0XCrQ8YgopTFqXjMSwt72/exec', {
            method: 'POST', body: data, mode: 'no-cors'
        }).then(() => {
            form.style.display = 'none';
            form.parentElement.querySelector('.email-success').style.display = 'block';
        });
    }
    </script>


    <footer>
        <div class="footer-inner">
            <p>¬© 2026 glp1.md ¬∑ Part of <a href="https://thrive.md" style="color: var(--accent); text-decoration: none;">thrive.md</a></p>
            <p style="margin-top: 8px; font-size: 12px;">Eligibility criteria from FDA-approved prescribing information. This is not medical advice. Always consult your healthcare provider.</p>
        </div>
    </footer>
</body>
</html>
